Valeant under magnifying glass of research reports coverage on healthcare stocks
February 23, 2017Stock-Callers.com dedicated on Thursday its attention to four healthcare stocks, including a Canada-based Pharmaceutical company Valeant Pharmaceuticals International. Others were CVS Health Corp., Express Scripts Holding, and UnitedHealth Group.
According to Deloitte Global’s report, “2017 Global Health Care Outlook: Making Progress Against Persistent Challenges,” global health care expenditures are projected to reach $8.7 trillion by 2020, to be driven by an aging population and associated chronic disease, innovative clinical advancements, and rising technology and labor costs.
According to stock-callers.com, the resaon to put focus on Valeant Pharmaceuticals is that it’s stock finished Wednesday’s session 0.30% lower at $16.35 with a total trading volume of 9.69 million shares. The company’s shares have advanced 16.87% in the past month and 12.60% on an YTD basis. The stock is trading above its 50-day moving average by 10.63%. Furthermore, shares of Valeant Pharmaceuticals International, which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide, have a Relative Strength Index (RSI) of 63.76, the portal says.
On February 14, 2017, research firm RBC Capital Markets reiterated its ‘Sector Perform’ rating on the company’s stock with a decrease of the target price from $29 a share to $22 a share.
On February 21, 2017, Valeant Pharma and EyeGate Pharmaceuticals announced signing a deal for worldwide commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
